Findings

What do systematic reviews say?

2,227 questions · 2,562 findings · 156 reviews · Oral Health

Sort:Best matchNewest Highest certainty Download CSV

No studies found 297 · 11.6%GRADE not reported 1,616 · 63.1%Very low 405 · 15.8%Low 144 · 5.6%Moderate 81 · 3.2%High 19 · 0.7%

EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)

Progression‐free survival · People with squamous cell carcinoma of the oral cavity or oropharynx

EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard… showed no clear difference in progression-free survival compared with standard therapy alone (radiotherapy or chemoradiotherapy); GRADE not reported.

2 findings from 1 review

Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes
24 to 70 months · Monoclonal antibody + chemoradiotherapy vs chemoradiotherapy alone
HR 1.08 [0.89, 1.32]
1 study · 891 participants
GRADE not reported
Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes
24 to 70 months · Monoclonal antibody + radiotherapy vs radiotherapy alone
HR 0.70 [0.54, 0.91]
1 study · 424 participants
GRADE not reported

Tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)

Progression‐free survival · People with squamous cell carcinoma of the oral cavity or oropharynx

It is very uncertain whether tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus… changes progression-free survival compared with standard therapy alone (radiotherapy or chemoradiotherapy) (very low certainty).

1 finding from 1 review

Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes
40 to 60 months
HR 0.80 [0.51, 1.28]
2 studies · 271 participants
Very low

EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)

Participant satisfaction · People with squamous cell carcinoma of the oral cavity or oropharynx

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes
24 to 70 months
No included studies addressed participant satisfaction (review-wide gap).
0 studies
No studies found

EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)

Costs (direct and indirect) · People with squamous cell carcinoma of the oral cavity or oropharynx

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes
24 to 70 months
No included studies addressed direct and indirect costs to participants and health services (review-wide gap).
0 studies
No studies found

EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)

Overall survival · People with squamous cell carcinoma of the oral cavity or oropharynx

EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard… probably leads to lower overall survival compared with standard therapy alone (radiotherapy or chemoradiotherapy) (moderate certainty).

1 finding from 1 review

Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes
24 to 70 months
HR 0.82 [0.69, 0.97]
3 studies · 1421 participants
Moderate

Non-specific immunotherapy (recombinant interleukin-2 or BCG cell wall preparation) plus standard therapy vs Standard therapy alone (radiotherapy or chemoradiotherapy)

Overall survival · People with squamous cell carcinoma of the oral cavity or oropharynx

2 findings from 1 review

Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes
24 to 70 months · BCG cell wall preparation + surgery (Bier 1981)
BCG-CWP + surgery versus surgery alone: 3-year overall survival 10/10 vs 9/10; too few participants to calculate a hazard ratio (Bier 1981, 24 participants).
1 study · 24 participants
GRADE not reported
Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes
24 to 70 months · Recombinant interleukin-2 + surgery (De Stefani 2002)
HR 0.52 [0.31, 0.87]
1 study · 201 participants
Very low

Tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)

Overall survival · People with squamous cell carcinoma of the oral cavity or oropharynx

It is very uncertain whether tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus… changes overall survival compared with standard therapy alone (radiotherapy or chemoradiotherapy) (very low certainty).

1 finding from 1 review

Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes
40 to 60 months
HR 0.99 [0.62, 1.57]
2 studies · 271 participants
Very low

Tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)

Disease-free survival · People with squamous cell carcinoma of the oral cavity or oropharynx

It is very uncertain whether tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus… changes disease-free survival compared with standard therapy alone (radiotherapy or chemoradiotherapy) (very low certainty).

1 finding from 1 review

Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes
40 to 60 months · Gefitinib + radiotherapy (oral cavity)
HR 1.51 [0.61, 3.71]
1 study · 60 participants
Very low

Tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)

Locoregional control · People with squamous cell carcinoma of the oral cavity or oropharynx

It is very uncertain whether tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus… changes locoregional control compared with standard therapy alone (radiotherapy or chemoradiotherapy) (very low certainty).

1 finding from 1 review

Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes
40 to 60 months
HR 0.89 [0.53, 1.49]
2 studies · 271 participants
Very low

EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)

Locoregional control · People with squamous cell carcinoma of the oral cavity or oropharynx

EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard… probably leads to lower locoregional control compared with standard therapy alone (radiotherapy or chemoradiotherapy) (moderate certainty).

1 finding from 1 review

Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes
24 to 70 months
HR 0.68 [0.52, 0.89]
1 study · 424 participants
Moderate

Non-specific immunotherapy (recombinant interleukin-2 or BCG cell wall preparation) plus standard therapy vs Standard therapy alone (radiotherapy or chemoradiotherapy)

Locoregional control · People with squamous cell carcinoma of the oral cavity or oropharynx

1 finding from 1 review

Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes
24 to 70 months · Recombinant interleukin-2 + neoadjuvant chemotherapy (Mantovani 1998), tumour response
Response to treatment (Mantovani 1998; neoadjuvant chemotherapy + rIL-2 vs chemotherapy alone): complete response 4/13 vs 3/15; partial response 6/13 vs 9/15. Narrative only; no GRADE rating.
1 study · 33 participants
GRADE not reported

EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)

Quality of life · People with squamous cell carcinoma of the oral cavity or oropharynx

1 finding from 1 review

Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes
24 to 70 months
Only one study (Bonner 2006, 424 participants) comprehensively assessed quality of life using EORTC QLQ-C30 (v3.0) and QLQ-H&N35; no statistically significant difference between groups for global health status or any…
1 study · 424 participants
GRADE not reported

Systemic interventions (aciclovir, thalidomide, corticosteroids, rebamipide, etanercept, colchicine, interferon-alpha) vs placebo

Safety of the intervention (adverse effects) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care

1 finding from 1 review

Interventions for managing oral ulcers in Behçet's disease 2014 · Cochrane All outcomes
SoF 2 (systemic interventions vs placebo), grouped comment spanning all four listed outcomes (verbatim; the review's wording "topical" is a typo for systemic): "8 placebo-controlled trials evaluated topical…
Studies not reported
GRADE not reported

Sucralfate suspension (topical) vs Placebo suspension

Duration of episodes · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care

Sucralfate suspension (topical) showed no clear difference in mean duration of episodes compared with placebo suspension; GRADE not reported.

1 finding from 1 review

Interventions for managing oral ulcers in Behçet's disease 2014 · Cochrane All outcomes
End of treatment
MD -1.00 [-5.69, 3.69]
1 study · 35 participants
GRADE not reported

Interferon-alpha (topical lozenges) vs placebo

Total ulcer burden · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care

1 finding from 1 review

Interventions for managing oral ulcers in Behçet's disease 2014 · Cochrane All outcomes
Kilic 2009 (interferon-alpha lozenges 1000 IU or 2000 IU vs placebo, 84 patients; high risk of selective reporting): the data presented did not allow analysis; authors reported no statistically significant difference…
1 study · 84 participants
GRADE not reported

Interferon-alpha (topical lozenges) vs placebo

Quality of life · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care

1 finding from 1 review

Interventions for managing oral ulcers in Behçet's disease 2014 · Cochrane All outcomes
Kilic 2009 described the use of a quality of life assessment tool but did not report any quality of life data.
1 study · 84 participants
GRADE not reported

Topical triamcinolone acetonide vs Phenytoin syrup mouthwash (30 mg in 5 mL)

Positive response (not defined) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care

Triamcinolone acetonide 0.1% ointment (topical) led to higher positive response (not defined) compared with phenytoin syrup mouthwash (30 mg in 5 mL); GRADE not reported.

1 finding from 1 review

Interventions for managing oral ulcers in Behçet's disease 2014 · Cochrane All outcomes
7 days
RR 1.63 [1.13, 2.34]
1 study · 60 participants
GRADE not reported

Cyclosporin (systemic; 10 mg/kg/day for 16 weeks) vs Colchicine (systemic; 1 mg daily)

Safety of the intervention (adverse effects) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care

1 finding from 1 review

Interventions for managing oral ulcers in Behçet's disease 2014 · Cochrane All outcomes
Masuda 1989: multiple adverse events in the cyclosporin arm; 3 patients withdrew and 9 had a dose reduction as a result.
1 study · 92 participants
GRADE not reported

Sucralfate suspension (topical) vs Placebo suspension

Time to complete healing · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care

Sucralfate suspension (topical) showed no clear difference in healing time compared with placebo suspension; GRADE not reported.

1 finding from 1 review

Interventions for managing oral ulcers in Behçet's disease 2014 · Cochrane All outcomes
End of treatment (3 months)
MD -1.09 [-2.61, 0.43]
1 study · 30 participants
GRADE not reported

Sucralfate suspension (topical) vs Placebo suspension

Number of episodes · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care

Sucralfate suspension (topical) showed no clear difference in number of episodes compared with placebo suspension; GRADE not reported.

1 finding from 1 review

Interventions for managing oral ulcers in Behçet's disease 2014 · Cochrane All outcomes
End of treatment
MD 1.40 [-0.15, 2.95]
1 study · 35 participants
GRADE not reported